Related Experiment Video
Updated: May 18, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Halofuginone inhibits the establishment and progression of melanoma bone metastases
Patricia Juárez1, Khalid S Mohammad, Juan Juan Yin
1Division of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University Indianapolis, Walther Hall, C132 980 W Walnut Street, Indianapolis, IN 46202, USA.
Abstract:
TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometastatic factors that act on bone cells to change the skeletal microenvironment. Halofuginone is a plant alkaloid derivative that blocks TGF-β signaling with antiangiogenic and antiproliferative properties. Here, we show for the first time that halofuginone therapy decreases development and progression of bone metastasis caused by melanoma cells through the inhibition of TGF-β signaling. Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-β, and TGF-β-induced SMAD-driven transcription. In addition, halofuginone reduced expression of TGF-β target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. Also, cell apoptosis was increased in response to halofuginone. In nude mice inoculated with 1205 Lu melanoma cells, a preventive protocol with halofuginone inhibited bone metastasis. The beneficial effects of halofuginone treatment were comparable with those observed with other anti-TGF-β strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-β receptor I kinase, or forced overexpression of Smad7, a negative regulator of TGF-β signaling. Furthermore, mice with established bone metastases treated with halofuginone had significantly less osteolysis than mice receiving placebo assessed by radiography. Thus, halofuginone is also effective in reducing the progression of melanoma bone metastases. Moreover, halofuginone treatment reduced melanoma metastasis to the brain, showing the potential of this novel treatment against cancer metastasis.
Insights
Halofuginone therapy effectively inhibits melanoma bone metastasis by blocking TGF-β signaling. This treatment reduces tumor growth, prevents skeletal damage, and decreases spread to other organs like the brain.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis
Background:
- Transforming growth factor-beta (TGF-β) signaling in the bone microenvironment promotes melanoma bone metastasis.
- Halofuginone, a plant alkaloid derivative, exhibits antiangiogenic and antiproliferative properties by inhibiting TGF-β signaling.
Purpose of the Study:
- To investigate the efficacy of halofuginone in preventing and treating melanoma bone metastasis.
- To elucidate the mechanisms by which halofuginone affects melanoma cell behavior and bone metastasis progression.
Main Methods:
- In vitro studies using human melanoma cells to assess proliferation, SMAD protein phosphorylation, and TGF-β-induced gene transcription.
- In vivo studies using a mouse model of melanoma bone metastasis with preventive and therapeutic halofuginone treatment protocols.
- Radiographic analysis to evaluate osteolysis in mice with established bone metastases.
Main Results:
- Halofuginone inhibited melanoma cell proliferation, SMAD signaling, and TGF-β target gene expression (PTHrP, CTGF, CXCR4, IL11), while increasing apoptosis.
- Preventive halofuginone treatment significantly inhibited bone metastasis development in mice.
- Therapeutic halofuginone treatment reduced osteolysis in mice with established bone metastases and also decreased brain metastasis.
Conclusions:
- Halofuginone is a potent inhibitor of melanoma bone metastasis through TGF-β signaling blockade.
- Halofuginone demonstrates efficacy in both preventing the establishment and reducing the progression of melanoma bone metastases.
- Halofuginone shows potential as a novel therapeutic agent against melanoma metastasis to bone and brain.
